GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » Beneish M-Score

HCW Biologics (HCW Biologics) Beneish M-Score : 3.17 (As of May. 01, 2024)


View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 3.17 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for HCW Biologics's Beneish M-Score or its related term are showing as below:

HCWB' s Beneish M-Score Range Over the Past 10 Years
Min: 3.17   Med: 3.17   Max: 3.17
Current: 3.17

During the past 5 years, the highest Beneish M-Score of HCW Biologics was 3.17. The lowest was 3.17. And the median was 3.17.


HCW Biologics Beneish M-Score Historical Data

The historical data trend for HCW Biologics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics Beneish M-Score Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - - 3.17

HCW Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -5.29 -3.92 -0.39 3.17

Competitive Comparison of HCW Biologics's Beneish M-Score

For the Biotechnology subindustry, HCW Biologics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCW Biologics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Beneish M-Score falls into.



HCW Biologics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of HCW Biologics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 8.6926+0.528 * 1.9486+0.404 * 1.4072+0.892 * 0.4227+0.115 * 1.1851
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 3.8716+4.679 * -0.122291-0.327 * 2.6382
=3.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $1.54 Mil.
Revenue was 1.324 + 0.853 + 0.623 + 0.042 = $2.84 Mil.
Gross Profit was 0.253 + 0.175 + 0.12 + 0.013 = $0.56 Mil.
Total Current Assets was $6.40 Mil.
Total Assets was $28.51 Mil.
Property, Plant and Equipment(Net PPE) was $20.45 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.14 Mil.
Selling, General, & Admin. Expense(SGA) was $13.08 Mil.
Total Current Liabilities was $8.75 Mil.
Long-Term Debt & Capital Lease Obligation was $6.30 Mil.
Net Income was -10.681 + -4.939 + -4.304 + -5.071 = $-25.00 Mil.
Non Operating Income was 0.086 + 0.235 + 0.302 + 0.383 = $1.01 Mil.
Cash Flow from Operations was -3.895 + -5.589 + -9.392 + -3.638 = $-22.51 Mil.
Total Receivables was $0.42 Mil.
Revenue was 1.342 + 1.809 + 0.454 + 3.118 = $6.72 Mil.
Gross Profit was 0.268 + 0.362 + 0.167 + 1.789 = $2.59 Mil.
Total Current Assets was $34.07 Mil.
Total Assets was $46.81 Mil.
Property, Plant and Equipment(Net PPE) was $10.81 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.72 Mil.
Selling, General, & Admin. Expense(SGA) was $7.99 Mil.
Total Current Liabilities was $2.96 Mil.
Long-Term Debt & Capital Lease Obligation was $6.41 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.536 / 2.842) / (0.418 / 6.723)
=0.540464 / 0.062175
=8.6926

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.586 / 6.723) / (0.561 / 2.842)
=0.38465 / 0.197396
=1.9486

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6.404 + 20.453) / 28.514) / (1 - (34.071 + 10.805) / 46.809)
=0.058112 / 0.041295
=1.4072

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.842 / 6.723
=0.4227

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.718 / (0.718 + 10.805)) / (1.135 / (1.135 + 20.453))
=0.06231 / 0.052576
=1.1851

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(13.075 / 2.842) / (7.989 / 6.723)
=4.600633 / 1.188309
=3.8716

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((6.304 + 8.748) / 28.514) / ((6.41 + 2.956) / 46.809)
=0.527881 / 0.20009
=2.6382

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-24.995 - 1.006 - -22.514) / 28.514
=-0.122291

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

HCW Biologics has a M-score of 3.17 signals that the company is likely to be a manipulator.


HCW Biologics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of HCW Biologics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


HCW Biologics (HCW Biologics) Business Description

Traded in Other Exchanges
N/A
Address
2929 N Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong director, officer: Chief Executive Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam officer: Chief Financial Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers officer: SVP of Business Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene director C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao officer: VP of Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode officer: See Remarks C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd. 10 percent owner 16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057